[go: up one dir, main page]

MX2017003268A - Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. - Google Patents

Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.

Info

Publication number
MX2017003268A
MX2017003268A MX2017003268A MX2017003268A MX2017003268A MX 2017003268 A MX2017003268 A MX 2017003268A MX 2017003268 A MX2017003268 A MX 2017003268A MX 2017003268 A MX2017003268 A MX 2017003268A MX 2017003268 A MX2017003268 A MX 2017003268A
Authority
MX
Mexico
Prior art keywords
sdabs
single domain
directed against
domain antibodies
against intracellular
Prior art date
Application number
MX2017003268A
Other languages
English (en)
Other versions
MX379450B (es
Inventor
Singh Sunanda
Original Assignee
Singh Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singh Biotechnology Llc filed Critical Singh Biotechnology Llc
Publication of MX2017003268A publication Critical patent/MX2017003268A/es
Publication of MX379450B publication Critical patent/MX379450B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invencion provee composiciones y metodos para tratar una condicion o enfermedad sin el uso de secuencias dirigidas exogenas o composiciones quimicas. La presente invencion se relaciona con anticuerpos de un solo dominio (sdAbs), proteinas y polipeptidos que comprenden los sdAbs que estan dirigidos contra componentes intracelulares que causan una condicion o enfermedad. La invencion tambien incluye acidos nucleicos que codifican los sdAbs, proteinas y polipeptidos y composiciones que comprenden sdAbs. La invencion incluye el uso de composiciones, sdAbs y acidos nucleicos que codifican los sdAbs con propositos profilacticos, terapeuticos o de diagnostico.
MX2017003268A 2014-10-23 2015-10-23 Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares MX379450B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US201562210795P 2015-08-27 2015-08-27
PCT/US2015/057223 WO2016065323A2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens

Publications (2)

Publication Number Publication Date
MX2017003268A true MX2017003268A (es) 2017-08-02
MX379450B MX379450B (es) 2025-03-11

Family

ID=55761757

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003268A MX379450B (es) 2014-10-23 2015-10-23 Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
MX2021001098A MX2021001098A (es) 2014-10-23 2017-03-10 Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001098A MX2021001098A (es) 2014-10-23 2017-03-10 Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.

Country Status (24)

Country Link
US (4) US9663570B2 (es)
EP (3) EP3590962B1 (es)
JP (5) JP2017538671A (es)
KR (4) KR102207382B1 (es)
CN (2) CN111848793B (es)
AU (4) AU2015335600B2 (es)
BR (4) BR122020006907B8 (es)
CA (3) CA3052777C (es)
CY (2) CY1122035T1 (es)
DK (2) DK3590962T3 (es)
ES (2) ES2731876T3 (es)
HR (2) HRP20191056T1 (es)
HU (2) HUE057605T2 (es)
IL (2) IL289769B2 (es)
LT (2) LT3590962T (es)
MX (2) MX379450B (es)
PL (2) PL3590962T3 (es)
PT (2) PT3209685T (es)
RS (2) RS62694B1 (es)
RU (1) RU2017116710A (es)
SI (2) SI3590962T1 (es)
SM (2) SMT202100695T1 (es)
TW (1) TWI664289B (es)
WO (1) WO2016065323A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267784A1 (en) * 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
MX379450B (es) 2014-10-23 2025-03-11 Singh Biotechnology Llc Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
AU2016239951A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156465A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
WO2016156466A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
SG10201914118SA (en) 2015-09-01 2020-02-27 First Wave Bio Inc Methods and compositions for treating conditions associated with an abnormal inflammatory responses
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN112274649A (zh) * 2015-12-10 2021-01-29 希望之城 细胞穿透花青偶联抗体
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
JP7130274B2 (ja) 2017-12-22 2022-09-05 ロフィバイオ インコーポレイテッド 細胞内浸透能を有する抗ｓｔａｔ３二重特異性抗体およびこれを含む薬学的組成物
JP2021523115A (ja) * 2018-05-04 2021-09-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症性疾患または障害を治療するための方法および組成物
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
JP2023517222A (ja) 2020-03-11 2023-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 操作されたウイルス粒子を使用した遺伝子送達のための方法および組成物
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939A (zh) * 2021-04-14 2022-10-21 中山大学 一种融合蛋白及其制备方法与应用
EP4366772A4 (en) * 2021-07-07 2025-05-21 Singh Biotechnology, LLC SUPPRESSION OF UVEITIS BY SINGLE-DOMAIN ANTIBODIES
EP4392459A2 (en) * 2021-08-27 2024-07-03 Singh Biotechnology, LLC Therapeutic single domain antibody
AU2022409802A1 (en) 2021-12-15 2024-06-06 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
US12252512B2 (en) 2022-07-25 2025-03-18 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
TW202444412A (zh) 2023-02-04 2024-11-16 美商默門塔醫藥公司 用於治療胎兒及新生兒溶血性疾病之組成物及方法
WO2025004683A1 (ja) * 2023-06-30 2025-01-02 国立大学法人大阪大学 がん検査方法及びがん治療剤
WO2025027511A1 (en) 2023-07-30 2025-02-06 Janssen Biotech, Inc. Molecules that bind to mutant calreticulin and uses thereof
WO2025057086A2 (en) 2023-09-11 2025-03-20 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions of fcrn antibodies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025109518A1 (en) 2023-11-21 2025-05-30 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CA2378953A1 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
EA010570B1 (ru) * 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20100143371A1 (en) 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
WO2009033091A1 (en) 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
EP2323630B1 (en) * 2008-06-30 2014-11-19 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
CA2859226C (en) * 2011-12-20 2020-07-21 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
JP6542669B2 (ja) * 2012-10-31 2019-07-10 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 癌の治療
AU2014227824B2 (en) * 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2014153495A2 (en) * 2013-03-22 2014-09-25 University Of Hawaii Novel stat3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
MX386030B (es) 2013-08-29 2025-03-18 Hope City Conjugados de penetración celular y métodos de uso de estos.
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
MX379450B (es) 2014-10-23 2025-03-11 Singh Biotechnology Llc Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares

Also Published As

Publication number Publication date
RS59063B1 (sr) 2019-08-30
KR20190107199A (ko) 2019-09-18
US9695234B2 (en) 2017-07-04
PL3590962T3 (pl) 2022-01-31
HRP20191056T1 (hr) 2019-09-20
CA3114318A1 (en) 2016-04-28
KR20180021205A (ko) 2018-02-28
JP6928773B2 (ja) 2021-09-01
KR102207381B1 (ko) 2021-01-27
EP4006052A1 (en) 2022-06-01
AU2021200416B2 (en) 2022-06-09
BR122020006914B1 (pt) 2022-03-22
CN111848793A (zh) 2020-10-30
AU2015335600B2 (en) 2019-04-04
US20160115244A1 (en) 2016-04-28
JP7195400B2 (ja) 2022-12-23
US9546211B2 (en) 2017-01-17
PT3590962T (pt) 2021-12-15
MX379450B (es) 2025-03-11
JP2020015732A (ja) 2020-01-30
US20160115226A1 (en) 2016-04-28
SI3590962T1 (sl) 2022-02-28
CY1124867T1 (el) 2022-11-25
IL250961A0 (en) 2017-04-30
BR122020006918B1 (pt) 2022-03-15
AU2021200416A1 (en) 2021-02-25
JP2019142885A (ja) 2019-08-29
RS62694B1 (sr) 2022-01-31
IL250961B (en) 2022-02-01
ES2900253T3 (es) 2022-03-16
KR101831123B1 (ko) 2018-02-22
EP3209685B1 (en) 2019-04-24
CN111848793B (zh) 2023-08-18
IL289769A (en) 2022-03-01
CA3052777A1 (en) 2016-04-28
CN106852148B (zh) 2020-07-31
BR112017008165B1 (pt) 2020-04-22
BR122020006907B1 (pt) 2022-03-22
ES2731876T3 (es) 2019-11-19
AU2015335600A1 (en) 2017-03-16
KR102023289B1 (ko) 2019-09-19
AU2019204614A1 (en) 2019-07-18
BR122020006918B8 (pt) 2023-01-31
CA3052777C (en) 2021-06-01
HRP20211889T1 (hr) 2022-03-04
CA2962275C (en) 2019-11-05
WO2016065323A3 (en) 2016-06-16
TWI664289B (zh) 2019-07-01
JP2017538671A (ja) 2017-12-28
EP3209685A2 (en) 2017-08-30
CY1122035T1 (el) 2020-10-14
BR112017008165A2 (pt) 2018-03-06
WO2016065323A2 (en) 2016-04-28
AU2019204614B2 (en) 2020-10-22
CN106852148A (zh) 2017-06-13
EP3209685A4 (en) 2018-01-24
US20160115247A1 (en) 2016-04-28
DK3590962T3 (da) 2021-12-13
SMT202100695T1 (it) 2022-01-10
JP2021165278A (ja) 2021-10-14
SI3209685T1 (sl) 2019-10-30
CA2962275A1 (en) 2016-04-28
BR122020006907B8 (pt) 2023-01-31
HUE047601T2 (hu) 2020-05-28
EP3590962B1 (en) 2021-09-29
LT3590962T (lt) 2021-12-27
KR102207382B1 (ko) 2021-01-27
EP3590962A1 (en) 2020-01-08
JP6986180B2 (ja) 2021-12-22
US20160115248A1 (en) 2016-04-28
KR20190108646A (ko) 2019-09-24
RU2017116710A (ru) 2018-11-23
SMT201900413T1 (it) 2019-09-09
IL289769B1 (en) 2024-01-01
JP2022037002A (ja) 2022-03-08
PL3209685T3 (pl) 2020-01-31
PT3209685T (pt) 2019-06-27
KR20170070002A (ko) 2017-06-21
DK3209685T3 (da) 2019-07-29
HUE057605T2 (hu) 2022-06-28
IL289769B2 (en) 2024-05-01
BR122020006914B8 (pt) 2023-01-31
BR112017008165B8 (pt) 2020-10-27
LT3209685T (lt) 2019-08-26
MX2021001098A (es) 2021-03-31
US9663570B2 (en) 2017-05-30
TW201615834A (zh) 2016-05-01
JP6670963B2 (ja) 2020-03-25
AU2022204167A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
MX2020009394A (es) Anticuerpos anti-cd73 y métodos de uso de los mismos.
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
UY35964A (es) Anticuerpos humanos para pd?1
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2019004690A (es) Constructos de anticuerpos.
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR106556A1 (es) Anticuerpos de un solo dominio dirigidos contra antígenos extracelulares
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX373277B (es) Polipeptidos fhbp meningococicos modificados.
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR102421A1 (es) Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas